bs-12414R-A488 [Conjugated Primary Antibody]
AMHR2 Polyclonal Antibody, ALEXA FLUOR® 488 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: AMHR2

Immunogen Range: 21-120/573


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 269

Source: KLH conjugated synthetic peptide derived from human MISRII/AMHR2

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

MISR II is a 573 amino acid protein encoded by the human gene AMHR2. MISR II belongs to the protein kinase superfamily, TKL Ser/Thr protein kinase family, TGFB receptor subfamily and contains one protein kinase domain. Upon ligand binding, MISR II forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. These type II receptors rylate and activate type I receptors which autophosphorylate, then bind and activate Smad transcriptional regulators. MISR II also acts as a receptor for anti-Muellerian hormone. Defects in AMHR2 are the cause of persistent Muellerian duct syndrome type 2 (PMDS-2). PMDS-2 is a form of male pseudo-hermaphroditism characterized by a failure of Muellerian duct regression in otherwise normal males.

Conjugation: ALEXA FLUOR® 488

Excitation/ Emission: 490nm/525nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
FCM(1:20-100)

Predicted Molecular Weight: 61


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Dog
Pig
Horse

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Huang CC et al. Hyperactive CREB signaling pathway involved in the pathogenesis of polycystic ovarian syndrome revealed by patient-specific induced pluripotent stem cell modeling. Fertil Steril. 2019 Jul 2. pii: S0015-0282(19)30428-5. Read more>>
VALIDATION IMAGES